SBBP - Crinetics Pharma lead drug successful in mid-stage acromegaly study

A Phase 2 clinical trial, ACROBAT Edge, evaluating Crinetics Pharmaceuticals' (CRNX) lead candidate paltusotine (formerly CRN00808) for the treatment of acromegaly met the primary endpoint. Specifically, once-daily oral doses of paltusotine maintained insulin-like growth factor-1 (IGF-1) levels at Week 13 in acromegaly patients who switched from an injected somatostatin receptor ligand depot of either octreotide [Novartis' (NVS) Sandostatin] or lanreotide [Ipsen's (IPSEY) Somatuline] monotherapy.The company will host a key opinion leader event on Thursday, November 20.Acromegaly-related tickers: Chiasma (CHMA), Ionis Pharmaceuticals (IONS), Strongbridge Biopharma (SBBP), Acceleron Pharma (XLRN).Shares up 19% premarket on light volume.

For further details see:

Crinetics Pharma lead drug successful in mid-stage acromegaly study